BAL eotaxin and IL-5 in asthma, and the effects of inhaled corticosteroid and β2 agonist

Respirology

Volumn 9, Issue 4, 2004, Pages 507-513

  Feltis, Bryce N ^a   Reid, David W ^a   Ward, Chris ^b   Walters, E Haydn ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Cytokines; Eosinophils; Glucocorticoid; Inflammation

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; EOTAXIN; FLUTICASONE; INTERLEUKIN 5; SALMETEROL;

ARTICLE; ASTHMA; CELL COUNT; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DRUG DOSE REGIMEN; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LEUKOCYTE DIFFERENTIAL COUNT; LONGITUDINAL STUDY; LUNG CLEARANCE; LUNG LAVAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHODILATOR AGENTS; CHEMOKINES, CC; CROSS-SECTIONAL STUDIES; HUMANS; INTERLEUKIN-5; LONGITUDINAL STUDIES; TREATMENT OUTCOME;

EID: 13144251137     PISSN: 13237799     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2004.00624.x     Document Type: Article

References (28)

1. Pepys J, Simon G. Asthma, pulmonary eosinophilia, and allergic alveolitis. Med. Clin. North Am. 1973; 57: 573-91.
2. Wardlaw AJ, Kay AB. The role of the eosinophil in the pathogenesis of asthma. Allergy 1987; 42: 321-35.
3. Kay AB, Frew AJ, Moqbel R et al. The activated eosinophil in allergy and asthma. Prog. Clin. Biol. Res. 1989; 297: 183-97.
4. Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ. The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem. Biophys. Res. Commun. 1993; 197: 1167-72.
5. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J. Exp. Med. 1988; 167: 219-24.
6. Warren DJ, Moore MA. Synergism among interleukin 1, interleukin 3, and interleukin 5 in the production of eosinophils from primitive hemopoietic stem cells. J. Immunol. 1988; 140: 94-9.
7. Kitaura M, Nakajima T, Imai T et al. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J. Biol. Chem. 1996; 271: 7725-30.
8. Woo CH, Jeong DT, Yoon SB et al. Eotaxin induces migration of RBL-2H3 mast cells via a Rac-ERK-dependent pathway. Biochem. Biophys. Res. Commun. 2002; 298: 392-7.
9. Rothenberg ME, Ownbey R., Mehlhop PD et al. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol. Med. 1996; 2: 334-48.
10. Rothenberg ME, Luster AD, Lilly CM, Drazen JM, Leder P. Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung. J. Exp. Med. 1995; 181: 1211-16.
11. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J. Exp. Med. 1995; 182: 1169-74.
12. Walsh GM, Hartnell A, Wardlaw AJ, Kurihara K, Sanderson CJ, Kay AB. IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18) -dependent manner. Immunology 1990; 71: 258-65.
13. Sanderson CJ. Interleukin-5: an eosinophil growth and activation factor. Dev. Biol. Stand 1988; 69: 23-9.
14. Lilly CM, Nakamura H, Kesselman H et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J. Clin. Invest. 1997; 99: 1767-73.
15. Li X, Ward C, Thien F et al. An antiinflammatory effect of salmeterol, a long-acting beta (2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am. J. Respir. Crit. Care Med. 1999; 160: 1493-9.
16. Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern? Drug Saf. 1997; 16: 295-308.
17. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 1998; 158: 924-30.
18. Robinson DS, Ying S, Bentley AM et al. Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. J. Allergy Clin. Immunol. 1993; 92: 397-403.
19. Schmidt J, Fleissner S, Heimann-Weitschat I, Lindstaedt R, Szelenyi I. The effect of different corticosteroids and cyclosporin A on interleukin-4 and interleukin-5 release from murine TH2-type T cells. Eur. J. Pharmacol. 1994; 260: 247-50.
20. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144-8.
21. Lamkhioued B, Renzi PM, Abi-Younes S et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J. Immunol. 1997; 159: 4593-601.
22. Haslam PL, Baughman RP. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur. Respir. J. 1999; 14: 245-8.
23. Dente FL, Bancalari L, Bacci E et al. Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects. Thorax 1999; 54: 622-4.
24. Erjefalt JS, Persson CG. New aspects of degranulation and fates of airway mucosal eosinophils. Am. J. Respir. Crit. Care Med. 2000; 161: 2074-85.
25. Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X, Moilanen E, Barnes PJ. Delayed eosinophil apoptosis in asthma. J. Allergy Clin. Immunol. 2000; 106: 77-83.
26. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 2003; 167: 199-204.
27. Humbles AA, Conroy DM, Marleau S et al. Kinetics of eotaxin generation and its relationship to eosinophil accumulation in allergic airways disease: analysis in a guinea pig model in vivo. J. Exp. Med. 1997; 186: 601-12.
28. Bartels J, Schluter C, Richter E et al. Human dermal fibroblasts express eotaxin: molecular cloning, mRNA expression, and identification of eotaxin sequence variants. Biochem. Biophys. Res. Commun. 1996; 225: 1045-51.